Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neu-120 in PD with Levodopa-Induced Dyskinesia
NCT00607451Phase 2Terminated
- Sponsor
- Neurim Pharmaceuticals
- Start
- Mar 2008
- Primary completion
- Aug 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of NEU-120 in levodopa-induced dyskinesia (LID), sponsored by Neurim Pharmaceuticals. Started Mar 2008; status: terminated.
02
Drugs
NEU-120
03
Conditions
levodopa-induced dyskinesia (LID)
Beyond the preview
Go deeper on NCT00607451.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00607451.